Navigation Links
Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug

TSX-V: PGA

VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - Pacgen Biopharmaceuticals Corporation ("Pacgen") is pleased to report that topline results from its Phase I/II study of PAC-113, a novel antifungal, show it is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. Based on these results the Company plans to initiate a Phase IIb study to optimize PAC-113 dose and formulation.

"For many immunocompromised patients oral candidiasis can be severe, impacting their ability to get appropriate nutrition. We are very encouraged by the PAC-113 results and its potential to help patients with oral candidiasis, particularly when available treatments have a number of limitations and drawbacks," said Dr. Neil Reiner, Professor and Head of Division of Infectious Diseases, UBC Department of Medicine and Vancouver General Hospital, and a member of Pacgen's Clinical Advisory Board

PAC-113 is a peptide based anti-fungal drug candidate targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. The Phase I/II clinical trial of PAC-113 was conducted at sites in the United States and South Africa and recruited over 100 HIV seropositive patients with oral candidiasis.

The objective of this study was to provide safety data for PAC-113, as well as to establish first proof of efficacy for PAC-113 in eliminating clinical signs and symptoms of oral candidiasis. This Phase I/II study was a comparison between PAC-113 mouthrinse and Nystatin oral suspension. The study was a randomized, examiner-blinded, parallel design clinical trial that included a 14-day treatment phase, and a 14-day follow-up period, with a day 28 follow-up visit. Analyses were conducted on patients who were at least 80% compliant in the treatment phase.

Topline results show that 37% of PAC-113
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Consulting, a business unit of PAREXEL International (Nasdaq: ... serving the biopharmaceutical and medical device industries, today released ... provide key insights into emerging areas of biosimilar development. ... Consultant and Cecil Nick, B.Sc. (Hons), Vice President, Biotechnology, ...
... of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 2PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 3PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 4PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 2Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 3Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 4Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 6
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of ... special occasion dresses for the coming new year. ... dresses for global women. Now, all the models on ... 80% off. Among the new items, the model of ... is very popular. What’s more, Weddingshe.com also provides a ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 DePuy ... a metal-on-metal version of the artificial hip system ... state and federal courts, Bernstein Liebhard LLP reports. ... Bergen County Superior Court on December 2nd, counsel ... begin deposition of plaintiffs on November 19, 2014, ...
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer ... coming Christmas. In the promotion, all buyers worldwide can ... have something special for the women who are looking ... our new collections of 2015 dresses have been unveiled ... greatly discounted prices. Visit our website now before they ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... , LOS ANGELES, Dec. 21 Garcia Research ... US Hispanic marketing community, launched LATINOMICS(SM), The Hispanic Market Index(TM), ... political perspectives and other issues of the day within the ... survey of roughly 600 interviews was conducted, 400 by phone ...
... Mimotopes PepSets ... and Mycobacterium tuberculosis that can be targeted by new vaccines , ... Melbourne, Australia (PRWEB) December 21, 2009 -- Mimotopes Pty ... that it has been awarded a major supply agreement for the synthesis of peptide libraries ...
... ... YORK, Dec. 21 Jamie Oliver, celebrity chef and standard-bearer in the fight ... of the 2010 TED Prize, an award granting recipients $100,000 and something much ... , The host of 12 television series seen in 130 countries and bestselling ...
... , NASDAQ: CRME TSX: COM ... CRME / TSX: COM) today announced that it ... and employees (each a "restricted person") to adopt automatic securities ... Canadian and U.S. securities laws, including the guidance under Ontario ...
... , , FORT WORTH, Texas, ... Medicine (TCOM) offered a health screening for the homeless Friday, Dec. ... County. , Each Friday, 10 to 20 TCOM students from UNT ... Fort Worth,s Day Resource Center -- one of the main ...
... from Boston University School of Medicine (BUSM) have discovered a ... The study, which appears on-line in the Journal of ... in lung tissue for a lifetime after only a single ... inherited form of emphysema seen in young people due to ...
Cached Medicine News:Health News:Latinos Overwhelmingly Support Health Care Reform 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 3Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 4Health News:Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize 2Health News:Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize 3Health News:Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize 4Health News:Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize 5Health News:Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize 6Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 2Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 3Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 5Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 6Health News:TCOM Students Care for Homeless at Day Resource Center 2Health News:Researchers discover gene therapy to prevent progression of emphysema 2
The ISI Digi Grip has the strength needed for secure ,upper extremity traction....
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
... portable TeleMon companion monitor, and IntelliVue ... and monitoring solution for ambulating patients ... and SpO2. Clinicians can get access ... from the central station, monitoring cockpit, ...
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Medicine Products: